BioView

Company Overview

Snapshot

Founded in August 1998 by Yuval Harari, BioView operates with 11–50 employees. The company has raised $8.33M across two funding rounds. BioView became public on TASE in July 2006.

Business overview

BioView develops, manufactures, and markets automated cell-imaging and analysis solutions for cytology, cytogenetic, pathology, clinical, and research laboratories. The company's core technology leverages proprietary imaging, analysis, and review systems to control fully motorized fluorescent and bright-field microscopes, automating processes and reducing turnaround times for labor-intensive tests. BioView serves the health tech and life sciences sectors, with products like the DUET imaging and analysis platform, which has received FDA clearance for various FISH applications in cancer detection and genetic aberration diagnosis.

Strategic signal

In January 2026, BioView signed a memorandum of understanding to sell its LiquidView operations to a Nasdaq-listed company. This strategic move indicates a potential shift in the company's focus, streamlining its portfolio and potentially enhancing shareholder value through a significant asset divestiture to a major market player.

Company Intelligence Q&A

What is BioView's primary focus?

BioView specializes in developing, manufacturing, and marketing automated cell-imaging and analysis solutions for various laboratory and clinical applications, including cytology, cytogenetics, pathology, and research.

When did BioView go public?

BioView became a public company, listing on the TASE, in July 2006.

What significant agreement did BioView sign in January 2026?

In January 2026, BioView signed a memorandum of understanding for the sale of its LiquidView operations to a NASDAQ-listed company.

Has BioView collaborated with other companies on technology development?

Yes, in October 2019, BioView collaborated with RSIP Vision to use artificial intelligence for chromosome classification to improve genetic testing results. Additionally, in March 2018, BioView announced a collaboration with Vortex Biosciences to develop an integrated workflow for clinical biomarker identification on circulating tumor cells.

What regulatory approvals does BioView hold for its products?

BioView's DUET imaging and analysis platform has received FDA clearance for several FISH applications for cancer detection and diagnosis. The company's products also hold CE marking and approvals from Korean, Australian, and Thai FDA authorities.